SEC Company Response from Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083) (SNOA) — Nov 16, 2018
Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)
Date: Nov. 16, 2018 · CIK: 0001367083 · Accession: 0001683168-18-003471
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227806
Letter
Dawson James Securities, Inc.
1 North Federal Highway, 5th Floor
Boca Raton, FL 33432
November 16, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Sonoma Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-227806
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as placement agent for the proposed offering, hereby joins the request of Sonoma Pharmaceuticals, Inc. that the effective date of the above-referenced Registration Statement on Form S-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Friday, November 16, 2018, or as soon as practicable thereafter.
In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that on November 16, 2018, approximately 1700 copies of the preliminary prospectus dated November 16, 2018 were distributed to placement agents, dealers, institutions and others.
The undersigned advise that the placement agents have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Sincerely,
Dawson James Securities, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Dawson James Securities, Inc.
1 North Federal Highway, 5th Floor
Boca Raton, FL 33432
November 16, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Sonoma Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-227806
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as placement agent for the proposed
offering, hereby joins the request of Sonoma Pharmaceuticals, Inc. that the effective date of the above-referenced Registration
Statement on Form S-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Friday, November 16, 2018, or as soon as practicable
thereafter.
In connection with
this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that on November 16, 2018, approximately
1700 copies of the preliminary prospectus dated November 16, 2018 were distributed to placement agents, dealers, institutions and
others.
The undersigned advise
that the placement agents have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934,
as amended.
Sincerely,
Dawson James Securities, Inc.
By: /s/ Robert D. Keyser, Jr.
Name: Robert D. Keyser, Jr.
Title: CEO